作者
Caitlin N. Murphy,Randal C. Fowler,Joan Miquel Balada-Llasat,Amanda Carroll,Hanna Stone,Oluseun Akerele,Blake W. Buchan,Sam Windham,Amanda Hopp,Shira Ronen,Ryan F. Relich,Rebecca J. Buckner,Del A Warren,Romney M. Humphries,Shelly Campeau,Holly Huse,Suki Chandrasekaran,Amy Leber,Kathy Everhart,Amanda Harrington,Christina Kwong,Andrew Bonwit,Jennifer Dien Bard,Samia N. Naccache,Cynthia Zimmerman,Barbara E. Jones,Cory Rindlisbacher,Maggie Buccambuso,Angela Clark,Margarita B. Rogatcheva,Corrin Graue,Kevin M. Bourzac
摘要
The ability to provide timely identification of the causative agents of lower respiratory tract infections can promote better patient outcomes and support antimicrobial stewardship efforts. Current diagnostic testing options include culture, molecular testing, and antigen detection. These methods may require collection of various specimens, involve extensive sample treatment, and can suffer from low sensitivity and long turnaround times. This study assessed the performance of the BioFire FilmArray Pneumonia Panel (PN panel) and Pneumonia Plus Panel (PNplus panel), an FDA-cleared sample-to-answer assay that enables the detection of viruses, atypical bacteria, bacteria, and antimicrobial resistance marker genes from lower respiratory tract specimens (sputum and bronchoalveolar lavage [BAL] fluid).